title: Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors.
authors.affiliation: Department of Hematology and Oncology, Marienhospital Herne, University of Bochum, Herne, Germany. dirk.strumberg@marienhospital-herne.de
authors.forename: Dirk
authors.initials: D
authors.lastname: Strumberg
authors.forename: Beate
authors.initials: B
authors.lastname: Schultheis
authors.forename: Ulrich
authors.initials: U
authors.lastname: Traugott
authors.forename: Christiane
authors.initials: C
authors.lastname: Vank
authors.forename: Ansgar
authors.initials: A
authors.lastname: Santel
authors.forename: Oliver
authors.initials: O
authors.lastname: Keil
authors.forename: Klaus
authors.initials: K
authors.lastname: Giese
authors.forename: Jörg
authors.initials: J
authors.lastname: Kaufmann
authors.forename: Joachim
authors.initials: J
authors.lastname: Drevs
mesh_terms: D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D011493:Protein Kinase C / Q000235:genetics*; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D034741:RNA, Small Interfering; C061570:protein kinase N; D011493:Protein Kinase C; C561746:Atu027